A small molecule NNMT inhibitor that promotes metabolic reprogramming by reactivating the SAM cycle, showing anti-obesity and anti-aging effects in preclinical models.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →5-Amino-1MQ is a membrane-permeable small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in the regulation of cellular energy metabolism, NAD+ availability, and adipocyte biology. Its full chemical name is 5-amino-1-methylquinolinium, and it belongs to a class of compounds that have attracted significant preclinical research interest for their potential to modulate metabolic rate, reduce adiposity, and influence the biology of cellular aging — without the appetite suppression or central nervous system effects that characterize most other experimental anti-obesity compounds.
NNMT is an enzyme that transfers a methyl group from S-adenosylmethionine (SAM) to nicotinamide (a form of vitamin B3), producing N1-methylnicotinamide (MeNAM) and S-adenosylhomocysteine (SAH). This methylation reaction has two metabolically significant consequences: it consumes SAM, the universal methyl donor used in hundreds of other cellular methylation reactions, and it consumes nicotinamide before it can enter the NAD+ salvage pathway — the cellular route through which nicotinamide is recycled back into NAD+, the critical coenzyme central to mitochondrial energy generation and sirtuin enzyme activity.
NNMT is highly expressed in white adipose tissue, liver, and certain cancer cell types, and its expression is upregulated in obesity, type 2 diabetes, and aging — all conditions associated with declining NAD+ levels and impaired mitochondrial function. The hypothesis driving 5-amino-1MQ research is that excessive NNMT activity in adipose tissue and liver drives a metabolic inefficiency that promotes fat accumulation: by consuming nicotinamide and SAM, overactive NNMT reduces NAD+ availability for mitochondrial energy generation and sirtuin activation, while also depleting the methyl donor pool needed for normal epigenetic regulation.
5-Amino-1MQ was developed as a competitive inhibitor of NNMT that is small enough and lipophilic enough to cross cell membranes readily — hence the “membrane-permeable” descriptor that distinguishes it from earlier, less cell-penetrant NNMT inhibitors. By blocking NNMT, the compound is proposed to redirect nicotinamide toward NAD+ synthesis, restore the SAM pool for methylation reactions, and ultimately increase cellular energy expenditure in a way that drives fat loss without necessarily suppressing appetite or increasing locomotor activity.
All published 5-amino-1MQ research to date has been preclinical — conducted in cell culture systems and rodent models of diet-induced obesity. No human clinical trials have been published as of 2026. The compound is at an early stage of development, which means both that its mechanisms are not yet fully validated in human biology and that the research base is still accumulating. Explore related metabolic research compounds in our peptide database.
Nicotinamide N-methyltransferase (NNMT) catalyzes the transfer of a methyl group from S-adenosylmethionine to the nitrogen-1 position of nicotinamide, producing N1-methylnicotinamide. The key metabolic consequence is that this reaction diverts nicotinamide away from the NAD+ salvage pathway — the route by which nicotinamide is phosphoribosylated by NAMPT (nicotinamide phosphoribosyltransferase) to form NMN (nicotinamide mononucleotide), which is then converted to NAD+. When NNMT is overactive, as occurs in obese adipose tissue, a disproportionate fraction of available nicotinamide is methylated and excreted rather than recycled into NAD+. This creates a functional NAD+ deficiency in adipocytes and liver cells that impairs the NAD+-dependent processes central to healthy mitochondrial function. 5-Amino-1MQ competes with nicotinamide for binding at the NNMT active site, blocking the methylation reaction and thereby increasing the nicotinamide available for the NAMPT-catalyzed step into NAD+. In preclinical models, this intervention measurably increases intracellular NAD+ concentrations in adipose tissue. The membrane permeability of 5-amino-1MQ is critical to its efficacy — NNMT is a cytosolic enzyme, and inhibitors that cannot cross the cell membrane cannot access their target at concentrations relevant to inhibiting the intracellular reaction.
The increase in intracellular NAD+ produced by NNMT inhibition has direct consequences for sirtuin enzyme activity. Sirtuins (SIRT1-7) are NAD+-dependent protein deacylases — enzymes that modify target proteins post-translationally in ways that regulate their activity, stability, and function. Their activity is directly rate-limited by NAD+ availability, meaning that when NAD+ declines (as in obesity and aging), sirtuin activity drops and the metabolic programs sirtuins control become less active. SIRT1, localized in the nucleus and cytoplasm, deacetylates and activates PGC-1alpha, the master transcriptional co-activator of mitochondrial biogenesis. When SIRT1 activity increases due to higher NAD+, PGC-1alpha is more active, driving increased expression of genes encoding mitochondrial electron transport chain components, fatty acid beta-oxidation enzymes, and other metabolic machinery. SIRT3, localized in the mitochondria, deacetylates and activates multiple mitochondrial enzymes including those in the electron transport chain and fatty acid oxidation pathways. Research on 5-amino-1MQ in adipocyte cell cultures found increased SIRT1 and SIRT3 activity alongside increased NAD+ levels and increased expression of PGC-1alpha target genes. The downstream result is a cell that has more mitochondria, more active mitochondria, and higher capacity for fatty acid oxidation — all of which should translate to greater energy expenditure and reduced fat storage.
The second major biochemical consequence of NNMT inhibition involves the methyl donor S-adenosylmethionine. NNMT consumes SAM as the methyl donor for every nicotinamide methylation reaction it catalyzes. When NNMT is hyperactive — as in obese adipose tissue where NNMT expression is elevated — the enzyme consumes disproportionate quantities of SAM, depleting the pool of this universal methyl donor. SAM is required for the methylation of DNA (cytosine methylation at CpG sites, a major epigenetic regulatory mechanism), histone proteins (H3K9me, H3K27me, and other marks central to chromatin organization and gene regulation), phosphatidylcholine synthesis (critical for membrane biology), and creatine synthesis (essential for muscle energy buffering). Depletion of SAM thus creates a broad cellular methylation deficiency that affects gene expression patterns, membrane function, and energy metabolism simultaneously. 5-Amino-1MQ, by blocking NNMT’s SAM consumption, restores SAM availability for these competing methylation reactions. Research suggests this contributes to changes in gene expression in adipocytes beyond what NAD+/sirtuin effects alone would explain — particularly affecting the expression of genes involved in adipogenic programming and lipid metabolism. The epigenetic dimension of NNMT biology, and the potential for NNMT inhibition to normalize aberrant adipose tissue gene expression patterns in obesity, is an active area of mechanistic investigation.
The most directly published evidence for 5-amino-1MQ’s anti-obesity effects comes from studies using diet-induced obese (DIO) mouse models — mice fed high-fat diets for prolonged periods until they develop obesity, metabolic syndrome, and insulin resistance analogous to human obesity phenotypes. Studies published by Kannt, Rajagopal, and colleagues examined the effects of systemic 5-amino-1MQ administration in DIO mice over periods of several weeks. Treated animals showed significantly lower body weight gain compared to vehicle-treated controls on the same high-fat diet. Importantly, food intake measurements confirmed that the treated animals did not eat less — caloric consumption was statistically indistinguishable between groups. This is the critical finding that distinguishes 5-amino-1MQ mechanistically from stimulant-based or appetite-suppressing anti-obesity compounds: the weight effect appears to be driven by increased energy expenditure rather than reduced intake. Body composition analysis (fat mass versus lean mass) showed that the weight difference was accounted for by fat mass reduction, with lean mass preserved. Adipose tissue from treated animals showed reduced adipocyte size (hypertrophy), smaller lipid droplets, and increased expression of genes involved in mitochondrial biogenesis and fatty acid oxidation compared to controls.
Adipocyte hypertrophy — the enlargement of individual fat cells due to excess lipid storage — is not just a passive consequence of obesity; it is a driver of metabolic dysfunction. Enlarged adipocytes are more prone to hypoxia (low oxygen), more likely to undergo necrotic cell death that triggers macrophage infiltration and adipose tissue inflammation, and more lipolytically active in ways that increase portal free fatty acid delivery to the liver. Adipocyte hypertrophy is associated with insulin resistance, dyslipidemia, and the full metabolic syndrome phenotype. Research on 5-amino-1MQ in DIO models consistently finds reduced adipocyte size in treated animals compared to controls fed the same diet. Histological analysis of adipose tissue sections shows smaller, more uniformly sized fat cells with less macrophage infiltration and lower expression of pro-inflammatory adipokines including TNF-alpha and IL-6. These findings suggest that 5-amino-1MQ’s effects operate at the level of adipocyte lipid storage and metabolism rather than simply reducing the number of fat cells — an important mechanistic distinction because fat cell number is largely fixed after adolescence in humans, while fat cell size is dynamically regulated throughout life.
The use of indirect calorimetry (measuring oxygen consumption, CO2 production, and the respiratory exchange ratio — the ratio of CO2 produced to O2 consumed) in 5-amino-1MQ animal studies has provided mechanistic insight into how the compound produces weight loss without appetite suppression. DIO mice treated with 5-amino-1MQ showed significantly higher oxygen consumption (VO2) and energy expenditure compared to controls, particularly during the dark phase of the light-dark cycle when mice are most active. The respiratory exchange ratio in treated animals trended toward values indicating greater relative fat oxidation — consistent with increased reliance on fatty acids as fuel, which would be expected if mitochondrial fatty acid oxidation capacity is enhanced through SIRT3 activation and PGC-1alpha-driven mitochondrial biogenesis. No significant differences in locomotor activity were detected between treated and control animals in published studies, which rules out increased physical activity as the explanation for higher energy expenditure and points instead to elevated resting metabolic rate. This energy expenditure-driven mechanism is scientifically important because it represents a fundamentally different strategy from appetite-suppressing compounds — increasing the metabolic cost of existing body mass rather than reducing the energy intake that builds that mass.
The relationship between NNMT activity, NAD+ availability, and the biology of cellular aging is an emerging and scientifically rich area of research that contextualizes 5-amino-1MQ beyond simple anti-obesity pharmacology. NAD+ decline is a well-documented feature of normal aging, observed across multiple tissues in both rodents and humans, and is considered a contributor to the age-associated decline in mitochondrial function, muscle strength, cognitive function, and metabolic health. NNMT expression and activity increase with obesity and aging, suggesting it may be a causal contributor to age-related NAD+ decline (by consuming nicotinamide before it can be converted to NAD+) rather than simply a passive correlate. Research groups investigating NNMT as an aging target have found that NNMT knockdown in animal models can extend healthspan markers and improve metabolic parameters in a manner resembling caloric restriction — a connection consistent with the known role of SIRT1 and SIRT3 in mediating many of caloric restriction’s benefits. 5-Amino-1MQ, by pharmacologically inhibiting NNMT, may partially recapitulate these effects. Studies measuring NAD+ levels, sirtuin activity, and mitochondrial function biomarkers in 5-amino-1MQ-treated adipose tissue have found patterns consistent with improved metabolic age — lower lactate/pyruvate ratios, higher mitochondrial membrane potential, and increased expression of longevity-associated gene programs. This aging biology connection positions NNMT inhibition as a potential intervention relevant to metabolic aging beyond its obesity applications.
5-Amino-1MQ research invites comparison with the more extensively studied strategy of supplementing NAD+ precursors — particularly nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — to raise intracellular NAD+ levels. Both approaches aim to increase NAD+ availability, but through opposite mechanisms: NR and NMN supply exogenous precursors to build more NAD+, while 5-amino-1MQ reduces the enzymatic consumption of endogenous nicotinamide by blocking NNMT. Theoretically, the two approaches could be complementary — combining precursor supplementation with NNMT inhibition might produce greater NAD+ elevation than either approach alone, since one increases supply while the other reduces enzymatic diversion. Preclinical comparison studies examining this combination hypothesis have shown additive or synergistic effects on NAD+ levels and metabolic parameters in some experimental systems. The mechanistic distinction also matters for tissue targeting: NNMT is particularly highly expressed in adipose tissue and liver (the primary target tissues for 5-amino-1MQ’s metabolic effects), while NR and NMN raise NAD+ more broadly. This suggests 5-amino-1MQ might produce more adipose-specific NAD+ elevation than systemic NAD+ precursor supplementation, though direct head-to-head tissue distribution comparisons remain to be published.
All dosing information for 5-amino-1MQ comes from preclinical animal studies, as no human clinical trials have been published. In the diet-induced obesity mouse studies, 5-amino-1MQ was typically administered at doses in the range of 1-10 mg/kg body weight via intraperitoneal injection or oral gavage, with some studies testing once-daily and others testing twice-daily administration schedules. The effective dose range producing measurable metabolic effects in these studies varied depending on the specific outcome measured and the route of administration. Extrapolating animal model doses to human-equivalent doses requires allometric scaling that substantially reduces the per-kilogram dose (typically by a factor of 6-12 depending on species), but human pharmacokinetics and pharmacodynamics for 5-amino-1MQ have not been established, making dose projections speculative. Our research calculators include allometric scaling tools, though these should be used with caution for compounds with no human data.
Preclinical 5-amino-1MQ research has used multiple administration routes including intraperitoneal injection (IP), oral gavage, and in some in vitro experiments, direct addition to cell culture media. IP injection is a common route in mouse pharmacology research that provides reliable systemic exposure but does not translate to human pharmaceutical development. Oral gavage studies have found that 5-amino-1MQ is orally bioavailable in rodents, which is consistent with its membrane-permeable, small molecule chemistry that predicts reasonable gastrointestinal absorption. The oral bioavailability data from rodent studies, while encouraging for the prospect of oral human dosing, requires specific human pharmacokinetic characterization before any confidence can be placed in human oral exposure projections.
The translation of 5-amino-1MQ from preclinical models to human research faces several design questions that the existing animal data does not fully resolve. Key pharmacokinetic parameters needed for human dose selection — oral bioavailability, volume of distribution, clearance half-life, tissue penetration including adipose tissue concentrations — have not been published for human subjects. The NNMT inhibition target engagement biomarkers that would confirm the compound is working as intended (particularly N1-methylnicotinamide levels in urine and plasma, and intracellular NAD+ levels in accessible cell types like peripheral blood mononuclear cells or subcutaneous adipose biopsies) need to be validated for human use. Phase I first-in-human studies would need to address safety, pharmacokinetics, dose-response for NNMT inhibition, and any early indicators of metabolic effects before proceeding to efficacy studies. This is standard pharmaceutical development path, and 5-amino-1MQ has not yet entered this pipeline as of early 2026.
5-Amino-1MQ is not approved for any pharmaceutical or supplement use. It has no regulatory status as a drug, food ingredient, or research compound in any major jurisdiction, and it has not been investigated under an IND (Investigational New Drug) application in a published context. It is in the earliest stage of the translational research pipeline — beyond basic biochemical characterization but before any formal human safety testing. This status means that any human use of 5-amino-1MQ would be entirely outside established regulatory frameworks and without the safety oversight that clinical trial frameworks provide. The AI peptide coach can provide additional context on the regulatory landscape for preclinical stage compounds like 5-amino-1MQ.
Published preclinical safety data for 5-amino-1MQ is limited to the animal model studies where it has been tested. In the diet-induced obesity mouse studies, 5-amino-1MQ at effective doses was generally well-tolerated without gross signs of toxicity, organ damage on histological examination, or behavioral abnormalities. Standard metabolic safety parameters — blood glucose, liver enzymes, kidney function markers, complete blood count — were not dramatically disrupted in published reports. However, formal preclinical toxicology studies of the type that precede human clinical trials (comprehensive organ toxicity panels, genotoxicity assays, reproductive toxicity, carcinogenicity studies) have not been published in the peer-reviewed literature for 5-amino-1MQ. This means the preclinical safety characterization remains incomplete relative to what would be required before first-in-human studies under regulatory oversight. The available animal data suggests a reasonable initial safety profile at the doses and durations studied, but the absence of formal toxicology data leaves significant uncertainty about safety at higher doses, with long-term administration, in disease states, or in combination with other compounds.
Understanding 5-amino-1MQ’s mechanism points to several theoretical safety questions worth considering even in the absence of published toxicology data. NNMT produces N1-methylnicotinamide as its product, and MeNAM is not merely a waste product — it has been shown in some research to have its own biological activity, including potential cardiovascular protective effects through prostacyclin release. Completely blocking MeNAM production through potent NNMT inhibition could theoretically affect any biological processes in which MeNAM itself plays a role, though the magnitude and clinical significance of this is unclear. The SAM pool redistribution effects of NNMT inhibition — while potentially beneficial for restoring normal methylation capacity — also mean that methyl group availability for all SAM-dependent reactions would be affected. Given SAM’s involvement in methylation of DNA and histones, strong NNMT inhibition has theoretical potential to alter gene expression programs broadly, which could have beneficial effects (normalizing obesity-associated epigenetic changes) or unintended ones (disrupting normal cellular gene regulation). These are theoretical concerns grounded in mechanistic reasoning and would need to be specifically examined in comprehensive preclinical toxicology programs.
The honest summary of 5-amino-1MQ’s safety and risk profile is that a great deal remains unknown. The positive preclinical efficacy signal is real and mechanistically coherent, but the compound has not been characterized with the depth of safety investigation that would be required for confident human use. Specifically: no human pharmacokinetic data exists; no formal organ toxicity studies have been published; no genotoxicity or carcinogenicity data is available; the effects on SAM-dependent processes beyond NNMT have not been comprehensively mapped; the interaction profile with other medications and supplements has not been studied; and the appropriate dose range for human exposure — where the NNMT inhibition benefit is sufficient to produce metabolic effects without excessive disruption of NNMT-dependent physiology — is entirely unknown. For a research compound at this stage of development, these gaps are normal and expected, but they make 5-amino-1MQ a compound where caution and appropriate scientific oversight are especially important. Our peptide database contains profiles on better-characterized NAD+ pathway compounds for comparison.
No, and the mechanisms are fundamentally different despite the shared connection to NAD+ biology. NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are NAD+ precursors — they supply raw material that the cell converts to NAD+ through biosynthetic pathways. 5-Amino-1MQ is an NNMT inhibitor — it blocks an enzyme that would otherwise consume nicotinamide before it can be converted to NAD+. In simple terms, NMN and NR increase the supply of NAD+ building blocks, while 5-amino-1MQ reduces the waste of those building blocks. Both approaches result in higher intracellular NAD+, but through entirely different mechanisms with different pharmacological profiles, tissue distributions, and potential side effect considerations. They could theoretically be complementary strategies, and some researchers have explored combining them.
This is the mechanistically distinctive aspect of the compound that has attracted research attention. Most experimental obesity compounds — including most approved obesity drugs — achieve weight loss by reducing food intake, either by suppressing appetite or by reducing fat absorption from the gut. These approaches work against the body’s hunger signaling, which is why appetite suppression and nausea are so commonly associated with them. 5-Amino-1MQ, by enhancing mitochondrial energy generation capacity in adipocytes through NNMT inhibition and NAD+/sirtuin activation, appears to increase the metabolic cost of existing fat tissue — essentially increasing how much energy the body burns at rest. This is an energy expenditure mechanism rather than an intake-reducing mechanism, which is why appetite is preserved. Whether this mechanism translates to human biology with the same appetite-neutral profile seen in mice remains to be determined, but the mechanistic rationale is coherent.
NNMT (nicotinamide N-methyltransferase) is a metabolic enzyme that methylates nicotinamide, a form of vitamin B3. Its activity has two metabolic consequences: it consumes nicotinamide before it can be converted to NAD+, and it consumes S-adenosylmethionine (the universal methyl donor). NNMT is upregulated in obesity, type 2 diabetes, and aging — conditions where NAD+ decline and impaired mitochondrial function are features. The research hypothesis is that overactive NNMT in obese adipose tissue contributes to the metabolic dysfunction of obesity by reducing NAD+ availability and depleting the SAM pool. Inhibiting NNMT therefore has potential to partially reverse these metabolic deficiencies. NNMT has also been identified as overexpressed in several cancer types, adding an oncology dimension to NNMT inhibitor research that is distinct from the obesity/metabolic application.
As of early 2026, no human clinical trial data for 5-amino-1MQ has been published in the peer-reviewed literature. All mechanistic and efficacy evidence comes from cell culture experiments and rodent models. This is a critical distinction that distinguishes 5-amino-1MQ from compounds like tesamorelin or even MK-677, which have extensive human trial data. The preclinical evidence for 5-amino-1MQ is interesting and mechanistically coherent, but whether the observed effects in mice translate to humans — and at what doses, with what side effects — is simply not known yet. The compound appears to be in early-stage research without a clear commercial development pathway announced as of this date.
Sirtuins (SIRT1-7) are NAD+-dependent enzymes that regulate gene expression, mitochondrial function, DNA repair, and cellular metabolism. Their activity is rate-limited by NAD+ availability — when NAD+ is low, sirtuin activity is reduced. 5-Amino-1MQ’s NNMT inhibition increases intracellular NAD+ levels, which then increases the substrate available for sirtuin-catalyzed reactions. SIRT1 (nuclear/cytoplasmic) and SIRT3 (mitochondrial) are particularly relevant to the metabolic effects: SIRT1 activates PGC-1alpha to drive mitochondrial biogenesis, and SIRT3 activates mitochondrial fatty acid oxidation enzymes. Research on 5-amino-1MQ in adipocytes has found increased SIRT1 and SIRT3 activity alongside NAD+ elevation, suggesting that the sirtuin pathway is a genuine mechanistic component of the compound’s metabolic effects rather than a theoretical connection.
5-Amino-1MQ is indeed a quinolinium compound — its core chemical structure is based on the quinoline ring system, a bicyclic aromatic structure also found in several established drug classes including some antimalarials (chloroquine, mefloquine), antibacterials (fluoroquinolones), and cardiovascular drugs. The quinolinium designation indicates a positively charged nitrogen in the ring. This chemical class relationship does not mean 5-amino-1MQ has the same biological activities as these other quinoline drugs — the specific substituents and the methylated, positively charged nitrogen give it its NNMT inhibitor specificity. However, awareness of the chemical class can be relevant for thinking about potential off-target activities and cross-reactivity concerns in comprehensive safety evaluation.
The mechanistic rationale for combining 5-amino-1MQ with NAD+ precursors like NMN or NR is scientifically coherent — one reduces NAD+ consumption by blocking NNMT, the other increases NAD+ precursor supply. Preclinical research has explored this combination and found additive effects on NAD+ levels in some experimental contexts. However, no human combination data exists, and the safety and pharmacodynamic profile of this combination in humans has not been characterized. From a research perspective, understanding the interaction profile would be important for designing combination protocols. For general information on NAD+ pathway compounds and their relationships, our AI peptide coach can provide additional context.
Translating 5-amino-1MQ from preclinical research to a clinical treatment would require a substantial development program following established pharmaceutical development pathways. First, comprehensive preclinical toxicology and safety pharmacology (Ames test for mutagenicity, safety pharmacology panels for cardiac, CNS, and respiratory effects, 28-day and 90-day rodent and non-rodent toxicology studies) would need to be completed and reviewed. Then, an Investigational New Drug application would need to be filed with the FDA (or equivalent in other jurisdictions) before first-in-human studies could proceed. Phase I human pharmacokinetic and safety studies in healthy volunteers would establish human doses, bioavailability, and initial safety. Phase II proof-of-concept efficacy studies in relevant disease populations (likely obesity and/or metabolic syndrome) would be needed to establish human efficacy signals before large Phase III trials could justify the investment. This pathway typically requires 10-15 years and hundreds of millions of dollars. There is no indication as of early 2026 that 5-amino-1MQ has entered formal pharmaceutical development by any company.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.